Step Pharma nabs Series A funding
Paris-based Step Pharma, a developer of a novel class of oral nucleotide synthesis inhibitors, has secured 14.5 million euros in Series A financing. The investors included Pontifax, Kurma Partners, Bpifrance, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute.
22 November 2017•1 min read
